AlveoGene will use lentiviral vector technology and explore its application in other diseases, principally involving the lungs. The company's first target will be alpha-1 antitrypsin deficiency, a condition caused when a faulty gene fails to produce a protein that protects the lungs from damage when the body’s immune system is triggered to fight an infection or by irritants.